PMID- 28942393
OWN - NLM
STAT- MEDLINE
DCOM- 20181126
LR  - 20211204
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 104
IP  - 5
DP  - 2018 Mar
TI  - Prognostic value of galectin-3 in adults with congenital heart disease.
PG  - 394-400
LID - 10.1136/heartjnl-2017-312070 [doi]
AB  - OBJECTIVE: Galectin-3 is an emerging biomarker for risk stratification in 
      patients with heart failure. This study aims to investigate the release of 
      galectin-3 and its association with cardiovascular events in patients with adult 
      congenital heart disease (ACHD). METHODS: In this prospective cohort study, 602 
      consecutive patients with ACHD who routinely visited the outpatient clinic were 
      enrolled between 2011 and 2013. Galectin-3 was measured in thaw serum by batch 
      analysis. The association between galectin-3 and a primary endpoint of all-cause 
      mortality, heart failure, hospitalisation, arrhythmia, thromboembolic events and 
      cardiac interventions was investigated using multivariable Cox models. Reference 
      values and reproducibility were established by duplicate galectin-3 measurements 
      in 143 healthy controls. RESULTS: Galectin-3 was measured in 591 (98%) patients 
      (median age 33 (25-41) years, 58% male, 90% New York Heart Association (NYHA) 
      class I). Median galectin-3 was 12.7 (range 4.2-45.7) ng/mL and was elevated in 
      7% of patients. Galectin-3 positively correlated with age, cardiac medication 
      use, NYHA class, loss of sinus rhythm, cardiac dysfunction and N-terminal 
      pro-B-type natriuretic peptide (NT-proBNP). During a median follow-up of 4.4 (IQR 
      3.9-4.8) years, the primary endpoint occurred in 195 patients (33%). Galectin-3 
      was significantly associated with the primary endpoint in the univariable 
      analysis (HR per twofold higher value 2.05; 95% CI 1.44 to 2.93, p<0.001). This 
      association was negated after adjustment for NT-proBNP (HR 1.04; 95% CI 0.72 to 
      1.49, p=0.848). CONCLUSIONS: Galectin-3 is significantly associated with 
      functional capacity, cardiac function and adverse cardiovascular events in 
      patients with ACHD. Nevertheless, the additive value of galectin-3 to a more 
      conventional risk marker such as NT-proBNP seems to be limited.
CI  - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of 
      the article) 2018. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Baggen, Vivan J M
AU  - Baggen VJM
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
AD  - Cardiovascular Research School COEUR, Rotterdam, The Netherlands.
FAU - van den Bosch, Annemien E
AU  - van den Bosch AE
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
FAU - Eindhoven, Jannet A
AU  - Eindhoven JA
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
FAU - Menting, Myrthe E
AU  - Menting ME
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
FAU - Witsenburg, Maarten
AU  - Witsenburg M
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
FAU - Cuypers, Judith A A E
AU  - Cuypers JAAE
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
FAU - Boersma, Eric
AU  - Boersma E
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
AD  - Cardiovascular Research School COEUR, Rotterdam, The Netherlands.
AD  - Department of Clinical Epidemiology, Erasmus Medical Centre, Rotterdam, The 
      Netherlands.
FAU - Roos-Hesselink, Jolien W
AU  - Roos-Hesselink JW
AD  - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170923
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
RN  - 0 (Galectin 3)
RN  - 0 (Galectins)
RN  - 0 (LGALS3 protein, human)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Blood Proteins
MH  - Case-Control Studies
MH  - Female
MH  - Galectin 3/*blood
MH  - Galectins
MH  - Heart Defects, Congenital/*blood/diagnosis/mortality/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Up-Regulation
MH  - Young Adult
OTO - NOTNLM
OT  - Congenital Heart Disease
COIS- Competing interests: None declared.
EDAT- 2017/09/25 06:00
MHDA- 2018/11/27 06:00
CRDT- 2017/09/25 06:00
PHST- 2017/06/27 00:00 [received]
PHST- 2017/08/21 00:00 [revised]
PHST- 2017/08/23 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2018/11/27 06:00 [medline]
PHST- 2017/09/25 06:00 [entrez]
AID - heartjnl-2017-312070 [pii]
AID - 10.1136/heartjnl-2017-312070 [doi]
PST - ppublish
SO  - Heart. 2018 Mar;104(5):394-400. doi: 10.1136/heartjnl-2017-312070. Epub 2017 Sep 
      23.